Zosano Pharma Corporation reported impairment charges for the first quarter ended March 31, 2022. For the quarter, the company reported impairment loss of $25.9 million for the three months ended March 31, 2022, consists of the write-down of $24.8 million of property and equipment and $1.1 million of right-of-use assets.
Zosano Pharma Corporation
Equities
ZSAN
US98979H3012
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |